文献速递腹部技术与安全US

全氟丁烷增强超声靶向M2肿瘤相关巨噬细胞预测肝细胞癌程序性细胞死亡-1治疗反应

Perfluorobutane-enhanced US Targeting M2 Tumor-associated Macrophages for Predicting Programmed Cell Death-1 Response in Hepatocellular Carcinoma.
PubMed 文献 · Radiol Imaging Cancer · 2025-01-01

研究于2021年6月至2025年2月在动物模型中开展,体外实验显示M2型肿瘤相关巨噬细胞对全氟丁烷微泡的吞噬率为92%(46/50),而M1型为0%(P < .001)。体内实验中,造影后血管后期出现高增强环与M2型肿瘤相关巨噬细胞存在相关,且在抗PD-1治疗的原位肝移植小鼠模型中,高增强环阳性组与阴性组肿瘤进展存在差异(P < .05)。作者认为全氟丁烷微泡增强超声靶向M2型肿瘤相关巨噬细胞是预测肝细胞癌抗PD-1治疗反应的一种有前景的方法。

要点

  • 造影后血管后期高增强环与M2型肿瘤相关巨噬细胞存在相关。
  • M2型巨噬细胞对全氟丁烷微泡吞噬率92%(46/50),M1型为0%(P < .001)。
  • 抗PD-1治疗模型中,高增强环阳性组与阴性组肿瘤进展存在差异(P < .05)。

核心结论

  • 全氟丁烷微泡增强超声靶向M2型肿瘤相关巨噬细胞,是预测肝细胞癌抗PD-1治疗反应的一种有前景的方法。

研究设计与样本

  • 研究于2021年6月至2025年2月开展,使用4周龄雄性C57BL/6小鼠构建肝细胞癌模型、2-3月龄新西兰白兔构建VX2肝肿瘤模型;体内模型包括Akt/N-ras癌基因诱导的原发性肝细胞癌小鼠、原位肝内移植小鼠模型和VX2转移瘤兔模型;另建立原位肝移植小鼠模型,用增强超声显示高增强环并分析其与M2型肿瘤相关巨噬细胞分布及抗PD-1治疗效果的相关性。

关键影像表现/征象

  • 造影后血管后期出现高增强环与M2型肿瘤相关巨噬细胞的存在相关。
  • 体外透射显微镜证实M2型极化肿瘤相关巨噬细胞选择性摄取全氟丁烷微泡。

诊断标准与关键数值

  • 体外M2型巨噬细胞对全氟丁烷微泡吞噬率为92%(46/50),M1型巨噬细胞为0%(P < .001)。
  • 抗PD-1治疗的原位肝移植小鼠模型中,高增强环阳性组与阴性组肿瘤进展存在差异(P < .05)。

临床应用与阅片要点

  • 作者认为全氟丁烷微泡增强超声靶向M2型肿瘤相关巨噬细胞是预测肝细胞癌抗PD-1治疗反应的一种有前景的方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate the potential of perfluorobutane-enhanced US as a predictive biomarker for anti-programmed cell death (PD)-1 treatment response by targeting alternatively activated phenotype (M2)-polarized tumor-associated macrophages (TAMs) in hepatocellular carcinoma (HCC). Materials and Methods This study was conducted from June 2021 to February 2025. Male animal models included 4-week-old C57BL/6 mice for HCC models and 2-3-month-old New Zealand white rabbits for VX2 liver tumor models. The phagocytic capacity of M2-polarized TAMs for perfluorobutane microbubbles was evaluated in vitro using transmission microscopy to confirm selective microbubble uptake. In vivo, HCC models were established, including mice with primary HCC induced by Akt/N-ras oncogenes, an orthotopic intrahepatic transplantation mouse model, and a VX2 metastatic tumor rabbit model. Targeted imaging of M2-TAMs in these models was performed using perfluorobutane microsphere-based contrast-enhanced US, and the presence of hyperenhanced rims during the postvascular phase was analyzed to assess their association with M2-TAM accumulation. In addition, an orthotopic liver transplant mouse model was developed, in which contrast-enhanced US was used to depict hyperenhanced rims and analyze their correlation with M2-TAM distribution and the efficacy of anti-PD-1 therapy. Results In vitro studies demonstrated predominant uptake of perfluorobutane microbubbles by M2-TAMs, with 92% (46 of 50) of U937-derived M2 macrophages engulfing the microspheres compared with 0% of M1 macrophages (P < .001). In vivo, the observation of hyperenhanced rims during the postvascular phase of contrast-enhanced US was associated with the presence of M2-TAMs. In orthotopic liver transplant mouse models receiving anti-PD-1 treatment, tumor progression differed between the hyperenhanced rim-positive and rim-negative groups (P < .05). Conclusion Perfluorobutane microbubble-based contrast-enhanced US, which targets M2-TAMs, presents a promising method for predicting the response to anti-PD-1 therapy in HCC. Keywords: Contrast-enhanced Ultrasound, Tumor-associated Macrophages, Anti-PD-1 Treatment, Hepatocellular Carcinoma Supplemental material is available for this article. © RSNA, 2025.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Huang Z, Yue JQ, Zhu RH, et al. Perfluorobutane-enhanced US Targeting M2 Tumor-associated Macrophages for Predicting Programmed Cell Death-1 Response in Hepatocellular Carcinoma. Radiol Imaging Cancer. 2025. PMID: 40748245. doi:10.1148/rycan.240472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。